tiprankstipranks
DIH Holdings US, Inc Class A (DHAI)
OTHER OTC:DHAI
US Market

DIH Holdings US, Inc Class A (DHAI) AI Stock Analysis

69 Followers

Top Page

DHAI

DIH Holdings US, Inc Class A

(OTC:DHAI)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - 5.2)
Rating:42Neutral
Price Target:
$0.03
▼(-3.33% Downside)
Action:UpgradedDate:03/24/26
The score is driven primarily by weak financial performance—persistent and widening losses, a return to negative operating/free cash flow in 2025, and an ongoing negative equity position that elevates funding risk. Valuation is not meaningfully attractive due to negative earnings (negative P/E), and technical strength cannot be assessed with the missing indicator data.
Positive Factors
Strong gross margins
Gross margins in the low-50% range provide a durable cushion versus peers and input cost swings. Strong unit economics mean the business can reach operating profitability if SG&A and R&D spend are reined in, supporting margin sustainability over months.
Negative Factors
Consistently negative stockholders' equity
A persistent negative shareholders' equity position is a structural solvency concern that limits borrowing capacity, weakens creditor confidence, and heightens refinancing and covenant risk. This condition materially reduces financial flexibility absent a capital raise or sustained profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong gross margins
Gross margins in the low-50% range provide a durable cushion versus peers and input cost swings. Strong unit economics mean the business can reach operating profitability if SG&A and R&D spend are reined in, supporting margin sustainability over months.
Read all positive factors

DIH Holdings US, Inc Class A (DHAI) vs. SPDR S&P 500 ETF (SPY)

DIH Holdings US, Inc Class A Business Overview & Revenue Model

Company Description
DIH Holding US, Inc. operates as a robotics and virtual reality technology provider in the rehabilitation and human performance industry. The company is based in Norwell, Massachusetts....
How the Company Makes Money
null...

DIH Holdings US, Inc Class A Financial Statement Overview

Summary
Weak overall fundamentals: revenue turned negative in 2025 (~7% YoY decline), operating and net losses persist and widened in 2025, and operating/free cash flow deteriorated back to negative in 2025. The balance sheet is a major risk with consistently negative stockholders’ equity, limiting financial flexibility despite some debt reduction.
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
BreakdownMar 2025Jun 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue62.86M64.47M55.00M49.04M47.52M
Gross Profit32.21M29.77M34.54M24.77M28.23M
EBITDA-7.11M-6.20M652.00K-7.88M-9.63M
Net Income-8.68M-8.44M-2.36M-12.05M-10.85M
Balance Sheet
Total Assets26.75M35.73M35.73M34.02M38.78M
Cash, Cash Equivalents and Short-Term Investments1.94M3.23M3.23M3.31M3.16M
Total Debt11.96M15.95M15.95M23.63M17.09M
Total Liabilities63.89M68.28M68.28M60.44M54.96M
Stockholders Equity-37.13M-32.55M-32.55M-26.42M-16.18M
Cash Flow
Free Cash Flow-4.68M4.99M6.02M-1.71M-5.74M
Operating Cash Flow-4.14M5.19M6.18M-744.00K-4.99M
Investing Cash Flow-536.00K-202.00K-163.00K-969.00K-1.12M
Financing Cash Flow3.39M-4.95M-3.66M2.04M2.16M

DIH Holdings US, Inc Class A Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$6.49M-1.24-84.30%-20.05%41.89%
45
Neutral
$62.81M-1.011.02%-99.28%-46.17%
44
Neutral
$8.37M-0.56-193.22%-2.47%91.23%
43
Neutral
$1.00M-9.36-476.74%-5.19%-0.81%
42
Neutral
$20.93K>-0.01
40
Underperform
$7.17M-1.29-220.42%-41.03%35.71%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DHAI
DIH Holdings US, Inc Class A
0.01
-3.39
-99.71%
SSKN
Strata Skin Sciences
0.17
-2.34
-93.23%
BMRA
Biomerica
2.15
-1.96
-47.69%
PAVM
PAVmed
9.84
-10.56
-51.76%
TNON
Tenon Medical, Inc.
0.74
-0.35
-32.02%
HSCS
Heart Test Laboratories, Inc.
2.25
-1.25
-35.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 24, 2026